Co-Diagnostics Inc

For the period ended Dec 31, 2023. Filed Mar 14, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 14, 2024

CODX$0.32+24.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statement of Changes in Stockholders’ Equity

Convertible Preferred Stock · Common Stock · Treasury · Additional Paid-in · Accumulated Other Comprehensive · Accumulated · Total Stockholders’
Shares · Amount · Shares · Amount · Stock · Capital · Income · Earnings · Equity
Balance as of December 31, 2021	-	$	-	33,819,862	$33,820	$	-	$80,271,999	$	-	$54,169,280	$134,475,099
Common stock issued for option exercises	-		-	70,791	70		-	77,800		-	-	77,870
Common stock issued for warrant exercises	-		-	50,000	50		-	99,950		-	-	100,000
Stock-based compensation expense	-		-	725,166	725		-	7,542,498		-	-	7,543,223
Common stock issued for acquisitions	-		-	88,446	89		-	480,687		-	-	480,776
Repurchases of common stock	-		-	-	-		(14,211,866)	-		-	-	(14,211,866)
Other comprehensive income, net of tax	-		-	-	-		-	-		293,140	-	293,140
Net loss	-		-	-	-		-	-		-	(14,238,249)	(14,238,249)
Balance as of December 31, 2022	-	$	-	34,754,265	$34,754		$(14,211,866)	$88,472,935		$293,140	$39,931,031	$114,519,994
Stock-based compensation expense	-		-	1,354,081	1,354		-	8,335,501		-	-	8,336,855
Repurchases of common stock	-		-	-	-		(1,363,929)	-		-	-	(1,363,929)
Other comprehensive loss, net of tax	-		-	-	-		-	-		(146,440)	-	(146,440)
Net loss	-		-	-	-		-	-		-	(35,332,865)	(35,332,865)
Balance as of December 31, 2023	-	$	-	36,108,346	$36,108		$(15,575,795)	$96,808,436		$146,700	$4,598,166	$86,013,615

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.